25 XP   0   0   10

United Therapeutics Corporation
Buy, Hold or Sell?

Let's analyse United Therapeutics Corporation together

PenkeI guess you are interested in United Therapeutics Corporation. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of United Therapeutics Corporation. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about United Therapeutics Corporation

I send you an email if I find something interesting about United Therapeutics Corporation.

Quick analysis of United Therapeutics Corporation (30 sec.)










What can you expect buying and holding a share of United Therapeutics Corporation? (30 sec.)

How much money do you get?

How much money do you get?
$7.89
When do you have the money?
1 year
How often do you get paid?
70.0%

What is your share worth?

Current worth
$120.42
Expected worth in 1 year
$206.49
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
$93.96
Return On Investment
36.8%

For what price can you sell your share?

Current Price per Share
$255.14
Expected price per share
$241.37 - $258.31
How sure are you?
50%

1. Valuation of United Therapeutics Corporation (5 min.)




Live pricePrice per Share (EOD)

$255.14

Intrinsic Value Per Share

$71.64 - $144.69

Total Value Per Share

$192.06 - $265.11

2. Growth of United Therapeutics Corporation (5 min.)




Is United Therapeutics Corporation growing?

Current yearPrevious yearGrowGrow %
How rich?$5.9b$4.7b$1.1b19.9%

How much money is United Therapeutics Corporation making?

Current yearPrevious yearGrowGrow %
Making money$984.8m$727.3m$257.5m26.1%
Net Profit Margin42.3%37.6%--

How much money comes from the company's main activities?

3. Financial Health of United Therapeutics Corporation (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#12 / 1007

Most Revenue
#32 / 1007

Most Profit
#20 / 1007

Most Efficient
#33 / 1007

What can you expect buying and holding a share of United Therapeutics Corporation? (5 min.)

Welcome investor! United Therapeutics Corporation's management wants to use your money to grow the business. In return you get a share of United Therapeutics Corporation.

What can you expect buying and holding a share of United Therapeutics Corporation?

First you should know what it really means to hold a share of United Therapeutics Corporation. And how you can make/lose money.

Speculation

The Price per Share of United Therapeutics Corporation is $255.14. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of United Therapeutics Corporation.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in United Therapeutics Corporation, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $120.42. Based on the TTM, the Book Value Change Per Share is $21.52 per quarter. Based on the YOY, the Book Value Change Per Share is $15.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $1.97 per quarter.
Based on historical numbers we can estimate the returns while holding a share of United Therapeutics Corporation.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps19.817.8%19.817.8%15.005.9%10.724.2%10.924.3%
Usd Book Value Change Per Share21.528.4%21.528.4%15.206.0%12.234.8%9.593.8%
Usd Dividend Per Share1.970.8%1.970.8%1.940.8%1.010.4%0.950.4%
Usd Total Gains Per Share23.499.2%23.499.2%17.156.7%13.245.2%10.544.1%
Usd Price Per Share219.89-219.89-278.09-190.79-164.03-
Price to Earnings Ratio11.10-11.10-18.54-5.07-9.31-
Price-to-Total Gains Ratio9.36-9.36-16.22-153.97-89.58-
Price to Book Ratio1.83-1.83-2.81-2.16-3.01-
Price-to-Total Gains Ratio9.36-9.36-16.22-153.97-89.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share255.14
Number of shares3
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.971.01
Usd Book Value Change Per Share21.5212.23
Usd Total Gains Per Share23.4913.24
Gains per Quarter (3 shares)70.4739.72
Gains per Year (3 shares)281.87158.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12425827212147149
24751655424294308
37177583636440467
4951033111848587626
51181291140060734785
61421549168272881944
7166180719648510271103
8189206622469711741262
92132324252810913211421
102372582281012114681580

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%18.08.00.069.2%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%20.06.00.076.9%
Dividend per Share1.00.00.0100.0%2.00.01.066.7%4.00.01.080.0%7.00.03.070.0%9.00.017.034.6%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%22.04.00.084.6%

Fundamentals of United Therapeutics Corporation

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Fundamental data was last updated by Penke on 2024-04-12 21:12:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of United Therapeutics Corporation.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit United Therapeutics Corporation earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare United Therapeutics Corporation to the Biotechnology industry mean.
  • A Net Profit Margin of 42.3% means that $0.42 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of United Therapeutics Corporation:

  • The MRQ is 42.3%. The company is making a huge profit. +2
  • The TTM is 42.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ42.3%TTM42.3%0.0%
TTM42.3%YOY37.6%+4.8%
TTM42.3%5Y27.1%+15.2%
5Y27.1%10Y31.2%-4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ42.3%-207.2%+249.5%
TTM42.3%-218.5%+260.8%
YOY37.6%-282.4%+320.0%
5Y27.1%-432.2%+459.3%
10Y31.2%-593.8%+625.0%
1.1.2. Return on Assets

Shows how efficient United Therapeutics Corporation is using its assets to generate profit.

  • Above 5% is considered healthy but always compare United Therapeutics Corporation to the Biotechnology industry mean.
  • 13.7% Return on Assets means that United Therapeutics Corporation generated $0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of United Therapeutics Corporation:

  • The MRQ is 13.7%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 13.7%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ13.7%TTM13.7%0.0%
TTM13.7%YOY12.0%+1.7%
TTM13.7%5Y8.7%+5.0%
5Y8.7%10Y15.4%-6.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.7%-13.2%+26.9%
TTM13.7%-12.6%+26.3%
YOY12.0%-11.5%+23.5%
5Y8.7%-13.7%+22.4%
10Y15.4%-15.5%+30.9%
1.1.3. Return on Equity

Shows how efficient United Therapeutics Corporation is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare United Therapeutics Corporation to the Biotechnology industry mean.
  • 16.5% Return on Equity means United Therapeutics Corporation generated $0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of United Therapeutics Corporation:

  • The MRQ is 16.5%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 16.5%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ16.5%TTM16.5%0.0%
TTM16.5%YOY15.2%+1.3%
TTM16.5%5Y11.0%+5.4%
5Y11.0%10Y20.2%-9.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.5%-16.7%+33.2%
TTM16.5%-15.8%+32.3%
YOY15.2%-14.4%+29.6%
5Y11.0%-19.0%+30.0%
10Y20.2%-19.9%+40.1%

1.2. Operating Efficiency of United Therapeutics Corporation.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient United Therapeutics Corporation is operating .

  • Measures how much profit United Therapeutics Corporation makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare United Therapeutics Corporation to the Biotechnology industry mean.
  • An Operating Margin of 57.3% means the company generated $0.57  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of United Therapeutics Corporation:

  • The MRQ is 57.3%. The company is operating very efficient. +2
  • The TTM is 57.3%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ57.3%TTM57.3%0.0%
TTM57.3%YOY50.6%+6.7%
TTM57.3%5Y33.6%+23.7%
5Y33.6%10Y42.5%-8.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ57.3%-286.5%+343.8%
TTM57.3%-229.1%+286.4%
YOY50.6%-288.4%+339.0%
5Y33.6%-480.7%+514.3%
10Y42.5%-624.7%+667.2%
1.2.2. Operating Ratio

Measures how efficient United Therapeutics Corporation is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.49 means that the operating costs are $0.49 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of United Therapeutics Corporation:

  • The MRQ is 0.491. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.491. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.491TTM0.4910.000
TTM0.491YOY0.494-0.003
TTM0.4915Y0.677-0.186
5Y0.67710Y0.574+0.103
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4913.231-2.740
TTM0.4913.307-2.816
YOY0.4943.774-3.280
5Y0.6775.667-4.990
10Y0.5747.558-6.984

1.3. Liquidity of United Therapeutics Corporation.

1.3. Liquidity
1.3.1. Current Ratio

Measures if United Therapeutics Corporation is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.41 means the company has $4.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of United Therapeutics Corporation:

  • The MRQ is 4.414. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.414. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.414TTM4.4140.000
TTM4.414YOY9.849-5.435
TTM4.4145Y6.521-2.106
5Y6.52110Y5.136+1.384
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4143.890+0.524
TTM4.4144.182+0.232
YOY9.8495.343+4.506
5Y6.5216.135+0.386
10Y5.1366.453-1.317
1.3.2. Quick Ratio

Measures if United Therapeutics Corporation is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare United Therapeutics Corporation to the Biotechnology industry mean.
  • A Quick Ratio of 6.29 means the company can pay off $6.29 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of United Therapeutics Corporation:

  • The MRQ is 6.290. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.290. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.290TTM6.2900.000
TTM6.290YOY18.219-11.929
TTM6.2905Y12.039-5.749
5Y12.03910Y8.369+3.670
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2903.528+2.762
TTM6.2904.059+2.231
YOY18.2195.390+12.829
5Y12.0396.138+5.901
10Y8.3696.488+1.881

1.4. Solvency of United Therapeutics Corporation.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of United Therapeutics Corporation assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare United Therapeutics Corporation to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that United Therapeutics Corporation assets are financed with 16.5% credit (debt) and the remaining percentage (100% - 16.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of United Therapeutics Corporation:

  • The MRQ is 0.165. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.165. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.165TTM0.1650.000
TTM0.165YOY0.206-0.041
TTM0.1655Y0.232-0.067
5Y0.23210Y0.240-0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1650.339-0.174
TTM0.1650.337-0.172
YOY0.2060.273-0.067
5Y0.2320.368-0.136
10Y0.2400.391-0.151
1.4.2. Debt to Equity Ratio

Measures if United Therapeutics Corporation is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare United Therapeutics Corporation to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.8% means that company has $0.20 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of United Therapeutics Corporation:

  • The MRQ is 0.198. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.198. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.198TTM0.1980.000
TTM0.198YOY0.260-0.063
TTM0.1985Y0.306-0.108
5Y0.30610Y0.322-0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1980.388-0.190
TTM0.1980.403-0.205
YOY0.2600.342-0.082
5Y0.3060.432-0.126
10Y0.3220.461-0.139

2. Market Valuation of United Therapeutics Corporation

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings United Therapeutics Corporation generates.

  • Above 15 is considered overpriced but always compare United Therapeutics Corporation to the Biotechnology industry mean.
  • A PE ratio of 11.10 means the investor is paying $11.10 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of United Therapeutics Corporation:

  • The EOD is 12.876. Based on the earnings, the company is underpriced. +1
  • The MRQ is 11.097. Based on the earnings, the company is underpriced. +1
  • The TTM is 11.097. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD12.876MRQ11.097+1.779
MRQ11.097TTM11.0970.000
TTM11.097YOY18.544-7.447
TTM11.0975Y5.067+6.030
5Y5.06710Y9.308-4.241
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD12.876-2.249+15.125
MRQ11.097-2.553+13.650
TTM11.097-2.669+13.766
YOY18.544-4.107+22.651
5Y5.067-6.247+11.314
10Y9.308-6.499+15.807
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of United Therapeutics Corporation:

  • The EOD is 16.962. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 14.618. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 14.618. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD16.962MRQ14.618+2.343
MRQ14.618TTM14.6180.000
TTM14.618YOY20.321-5.703
TTM14.6185Y10.465+4.153
5Y10.46510Y13.702-3.236
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD16.962-2.858+19.820
MRQ14.618-3.288+17.906
TTM14.618-3.552+18.170
YOY20.321-5.560+25.881
5Y10.465-8.326+18.791
10Y13.702-8.881+22.583
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of United Therapeutics Corporation is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.83 means the investor is paying $1.83 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of United Therapeutics Corporation:

  • The EOD is 2.119. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.826. Based on the equity, the company is underpriced. +1
  • The TTM is 1.826. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.119MRQ1.826+0.293
MRQ1.826TTM1.8260.000
TTM1.826YOY2.812-0.986
TTM1.8265Y2.163-0.337
5Y2.16310Y3.014-0.852
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1191.929+0.190
MRQ1.8262.090-0.264
TTM1.8262.091-0.265
YOY2.8122.881-0.069
5Y2.1633.545-1.382
10Y3.0143.936-0.922
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of United Therapeutics Corporation.

3.1. Institutions holding United Therapeutics Corporation

Institutions are holding 97.016% of the shares of United Therapeutics Corporation.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc11.25190.029752950001833953.5878
2023-12-31Vanguard Group Inc9.93160.02254673678107670.2309
2023-12-31Wellington Management Company LLP8.06230.15553794010-327803-7.9529
2023-12-31venBio Select Advisor LLC6.07528.6832285888863880.2239
2023-12-31FMR Inc4.93220.03922321040-283749-10.8934
2023-12-31Renaissance Technologies Corp4.61170.73862170214-80294-3.5678
2023-12-31State Street Corporation4.13780.02081947177679073.6135
2023-12-31HHG PLC1.8490.1141870119-6449-0.7357
2023-12-31Geode Capital Management, LLC1.6570.0179779762-50484-6.0806
2023-12-31Dimensional Fund Advisors, Inc.1.19420.036156195099621.8047
2023-12-31Bank of New York Mellon Corp1.1770.0247553868-17200-3.0119
2023-12-31AQR Capital Management LLC1.17250.22725517677517915.7744
2023-12-31Nuveen Asset Management, LLC1.04450.0348491505-21876-4.2612
2023-12-31Farallon Capital Management, L.L.C.1.01150.51964760004760000
2023-12-31Morgan Stanley - Brokerage Accounts0.97690.008945973210533129.7209
2023-12-31NORGES BANK0.97140.0176457132106662.389
2023-12-31Fuller & Thaler Asset Management Inc0.91610.48034311162160.0501
2023-12-31Palo Alto Investors, LLC0.8417.8411395784-180123-31.2764
2023-12-31Orbimed Advisors, LLC0.82051.6955386100-15800-3.9313
2023-12-31LSV Asset Management0.80190.1811377368-5700-1.488
Total 63.436220.888429852210-43667-0.1%

3.2. Funds holding United Therapeutics Corporation

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv3.13360.02151474645-3300-0.2233
2024-03-28iShares Core S&P Mid-Cap ETF3.10730.39491462268-807-0.0552
2024-02-29Vanguard Small Cap Index2.57410.19451211331112540.9378
2023-12-31Vanguard Health Care Inv1.79050.399284259300
2024-02-29Vanguard Small Cap Value Index Inv1.75560.350682614042340.5151
2023-09-30Federated Hermes Kaufmann Small Cap Grow1.748082257000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.47450.153469385718140.2621
2023-12-31Vanguard Windsor Investor Shares1.15140.503541854-6138-1.1201
2024-03-28Pacer US Cash Cows 100 ETF0.97640.46744594728260.1801
2023-12-31FullerThaler Behavioral Small-Cap Equity0.86431.124640673200
2023-12-31FullerThaler Behavioral Sm-Cp Eq R60.86431.124940673200
2024-02-29SPDR® S&P MIDCAP 400 ETF Trust0.79660.402337485514100.3776
2024-03-28iShares Biotechnology ETF0.69130.9793325324-566-0.1737
2024-03-28SPDR® S&P Biotech ETF0.6680.956331435139601.2758
2024-02-29Hartford MidCap Y0.61941.0137291502-49612-14.5441
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.58520.148827540775002.7995
2024-02-29Fidelity Extended Market Index0.56220.155626457624900.9501
2023-12-31Janus Henderson Research D0.54740.294125760100
2023-12-31Janus Henderson US Research Growth Eq0.54740.294925760100
2023-12-31Worldwide Healthcare Ord0.47581.968122390000
Total 24.933310.947111733311-26935-0.2%

3.3. Insider Transactions

Insiders are holding 1.72% of the shares of United Therapeutics Corporation.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-10Martine A RothblattSELL13800237.27
2024-04-08Martine A RothblattSELL5060237.52
2024-04-04Martine A RothblattSELL15000233.27
2024-04-04Paul A MahonSELL6000232.37
2024-03-28Martine A RothblattSELL14125236.18
2024-03-27Nilda MesaSELL325237.8
2024-03-26Martine A RothblattSELL15000248.33
2024-03-22Martine A RothblattSELL15000237.05
2024-03-21Paul A MahonSELL6000236.45
2024-03-19Martine A RothblattSELL15000236.59
2024-02-23Christopher PatuskySELL1680224
2024-02-15Paul A MahonSELL6000215.31
2024-02-01Paul A MahonSELL6000215.01
2024-01-18Paul A MahonSELL6000218.72
2024-01-04Paul A MahonSELL6000227.97
2023-12-21Paul A MahonSELL6000229.27
2023-12-19Nilda MesaSELL605244.9
2023-12-12Christopher CauseySELL3000249.68
2023-12-07Paul A MahonSELL6000238.89
2023-11-02Paul A MahonSELL6000225.76

4. Summary

4.1. Key Performance Indicators

The key performance indicators of United Therapeutics Corporation compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--21.51721.5170%15.203+42%12.232+76%9.592+124%
Book Value Per Share--120.419120.4190%98.901+22%86.850+39%63.234+90%
Current Ratio--4.4144.4140%9.849-55%6.521-32%5.136-14%
Debt To Asset Ratio--0.1650.1650%0.206-20%0.232-29%0.240-31%
Debt To Equity Ratio--0.1980.1980%0.260-24%0.306-35%0.322-39%
Dividend Per Share--1.9721.9720%1.944+1%1.006+96%0.947+108%
Eps--19.81519.8150%14.996+32%10.718+85%10.916+82%
Free Cash Flow Per Share--15.04215.0420%13.685+10%9.490+59%9.326+61%
Free Cash Flow To Equity Per Share--14.80314.8030%15.239-3%12.468+19%7.925+87%
Gross Profit Margin--0.9170.9170%0.903+2%1.032-11%0.940-2%
Intrinsic Value_10Y_max--144.694--------
Intrinsic Value_10Y_min--71.641--------
Intrinsic Value_1Y_max--13.306--------
Intrinsic Value_1Y_min--8.875--------
Intrinsic Value_3Y_max--40.889--------
Intrinsic Value_3Y_min--25.354--------
Intrinsic Value_5Y_max--69.568--------
Intrinsic Value_5Y_min--40.270--------
Market Cap12006505690.000+9%10928533000.00010928533000.0000%13487365000.000-19%9184880879.000+19%7979523253.500+37%
Net Profit Margin--0.4230.4230%0.376+13%0.271+56%0.312+36%
Operating Margin--0.5730.5730%0.506+13%0.336+71%0.425+35%
Operating Ratio--0.4910.4910%0.494-1%0.677-27%0.574-14%
Pb Ratio2.119+14%1.8261.8260%2.812-35%2.163-16%3.014-39%
Pe Ratio12.876+14%11.09711.0970%18.544-40%5.067+119%9.308+19%
Price Per Share255.140+14%219.890219.8900%278.090-21%190.786+15%164.031+34%
Price To Free Cash Flow Ratio16.962+14%14.61814.6180%20.321-28%10.465+40%13.702+7%
Price To Total Gains Ratio10.862+14%9.3619.3610%16.217-42%153.972-94%89.585-90%
Quick Ratio--6.2906.2900%18.219-65%12.039-48%8.369-25%
Return On Assets--0.1370.1370%0.120+14%0.087+58%0.154-11%
Return On Equity--0.1650.1650%0.152+9%0.110+49%0.202-19%
Total Gains Per Share--23.48923.4890%17.148+37%13.238+77%10.539+123%
Usd Book Value--5984800000.0005984800000.0000%4796700000.000+25%4183200000.000+43%3053382100.000+96%
Usd Book Value Change Per Share--21.51721.5170%15.203+42%12.232+76%9.592+124%
Usd Book Value Per Share--120.419120.4190%98.901+22%86.850+39%63.234+90%
Usd Dividend Per Share--1.9721.9720%1.944+1%1.006+96%0.947+108%
Usd Eps--19.81519.8150%14.996+32%10.718+85%10.916+82%
Usd Free Cash Flow--747600000.000747600000.0000%663700000.000+13%458960000.000+63%451788900.000+65%
Usd Free Cash Flow Per Share--15.04215.0420%13.685+10%9.490+59%9.326+61%
Usd Free Cash Flow To Equity Per Share--14.80314.8030%15.239-3%12.468+19%7.925+87%
Usd Market Cap12006505690.000+9%10928533000.00010928533000.0000%13487365000.000-19%9184880879.000+19%7979523253.500+37%
Usd Price Per Share255.140+14%219.890219.8900%278.090-21%190.786+15%164.031+34%
Usd Profit--984800000.000984800000.0000%727300000.000+35%519640000.000+90%531071300.000+85%
Usd Revenue--2327500000.0002327500000.0000%1936300000.000+20%1776280000.000+31%1658758000.000+40%
Usd Total Gains Per Share--23.48923.4890%17.148+37%13.238+77%10.539+123%
 EOD+4 -4MRQTTM+0 -0YOY+28 -85Y+29 -710Y+27 -9

4.2. Fundamental Score

Let's check the fundamental score of United Therapeutics Corporation based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1512.876
Price to Book Ratio (EOD)Between0-12.119
Net Profit Margin (MRQ)Greater than00.423
Operating Margin (MRQ)Greater than00.573
Quick Ratio (MRQ)Greater than16.290
Current Ratio (MRQ)Greater than14.414
Debt to Asset Ratio (MRQ)Less than10.165
Debt to Equity Ratio (MRQ)Less than10.198
Return on Equity (MRQ)Greater than0.150.165
Return on Assets (MRQ)Greater than0.050.137
Total9/10 (90.0%)

4.3. Technical Score

Let's check the technical score of United Therapeutics Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5068.028
Ma 20Greater thanMa 50236.460
Ma 50Greater thanMa 100235.127
Ma 100Greater thanMa 200229.398
OpenGreater thanClose243.000
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets7,167,000
Total Liabilities1,182,200
Total Stockholder Equity5,984,800
 As reported
Total Liabilities 1,182,200
Total Stockholder Equity+ 5,984,800
Total Assets = 7,167,000

Assets

Total Assets7,167,000
Total Current Assets3,551,000
Long-term Assets3,616,000
Total Current Assets
Cash And Cash Equivalents 1,207,700
Short-term Investments 1,786,400
Net Receivables 278,900
Inventory 111,800
Other Current Assets 166,200
Total Current Assets  (as reported)3,551,000
Total Current Assets  (calculated)3,551,000
+/-0
Long-term Assets
Property Plant Equipment 1,045,400
Goodwill 33,700
Long Term Investments 1,909,800
Intangible Assets 80,500
Long-term Assets Other 151,800
Long-term Assets  (as reported)3,616,000
Long-term Assets  (calculated)3,221,200
+/- 394,800

Liabilities & Shareholders' Equity

Total Current Liabilities804,400
Long-term Liabilities377,800
Total Stockholder Equity5,984,800
Total Current Liabilities
Short-term Debt 400,000
Short Long Term Debt 400,000
Accounts payable 5,600
Other Current Liabilities 71,000
Total Current Liabilities  (as reported)804,400
Total Current Liabilities  (calculated)876,600
+/- 72,200
Long-term Liabilities
Long term Debt 300,000
Long-term Liabilities Other 77,800
Long-term Liabilities  (as reported)377,800
Long-term Liabilities  (calculated)377,800
+/-0
Total Stockholder Equity
Common Stock700
Retained Earnings 6,027,100
Accumulated Other Comprehensive Income -12,800
Other Stockholders Equity -30,200
Total Stockholder Equity (as reported)5,984,800
Total Stockholder Equity (calculated)5,984,800
+/-0
Other
Capital Stock700
Cash and Short Term Investments 2,994,100
Common Stock Shares Outstanding 49,700
Current Deferred Revenue327,800
Liabilities and Stockholders Equity 7,167,000
Net Debt -507,700
Net Invested Capital 6,684,800
Net Working Capital 2,746,600
Property Plant and Equipment Gross 1,473,600
Short Long Term Debt Total 700,000



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-31
> Total Assets 
18,700
59,900
250,645
212,121
184,566
179,502
207,158
291,413
478,550
587,018
871,319
1,051,544
1,431,635
1,518,079
1,626,595
2,087,567
1,884,410
2,184,445
2,325,600
2,879,400
3,401,000
3,913,400
4,615,000
5,169,100
6,044,500
7,167,000
7,167,0006,044,5005,169,1004,615,0003,913,4003,401,0002,879,4002,325,6002,184,4451,884,4102,087,5671,626,5951,518,0791,431,6351,051,544871,319587,018478,550291,413207,158179,502184,566212,121250,64559,90018,700
   > Total Current Assets 
16,800
52,700
222,120
69,003
141,857
89,721
110,492
166,757
277,374
352,461
297,447
324,507
765,054
562,455
668,470
909,013
974,197
1,275,335
1,424,800
1,447,900
1,768,000
1,864,500
2,167,200
2,323,600
3,380,300
3,551,000
3,551,0003,380,3002,323,6002,167,2001,864,5001,768,0001,447,9001,424,8001,275,335974,197909,013668,470562,455765,054324,507297,447352,461277,374166,757110,49289,721141,85769,003222,12052,70016,800
       Cash And Cash Equivalents 
6,800
18,300
200,935
24,373
122,655
68,562
82,586
69,180
91,067
139,323
129,452
100,352
252,162
162,676
154,030
278,889
397,697
831,798
1,023,000
705,100
669,200
738,400
738,700
894,800
961,200
1,207,700
1,207,700961,200894,800738,700738,400669,200705,1001,023,000831,798397,697278,889154,030162,676252,162100,352129,452139,32391,06769,18082,58668,562122,65524,373200,93518,3006,800
       Short-term Investments 
0
33,300
14,484
31,677
0
0
200
56,304
136,682
150,729
106,596
129,140
374,921
240,803
325,175
409,645
297,842
121,974
27,800
222,300
746,700
747,500
1,096,300
1,035,900
1,877,500
1,786,400
1,786,4001,877,5001,035,9001,096,300747,500746,700222,30027,800121,974297,842409,645325,175240,803374,921129,140106,596150,729136,68256,3042000031,67714,48433,3000
       Net Receivables 
100
400
2,351
4,224
9,659
10,612
14,766
18,807
25,579
29,662
30,600
53,264
73,707
88,680
116,626
126,297
162,287
192,827
214,500
297,100
175,700
151,400
157,400
198,700
220,400
278,900
278,900220,400198,700157,400151,400175,700297,100214,500192,827162,287126,297116,62688,68073,70753,26430,60029,66225,57918,80714,76610,6129,6594,2242,351400100
       Other Current Assets 
9,900
700
1,454
1,788
1,145
557
1,696
208
66
19,536
16,427
15,391
759,932
6,188
3,778
46,424
49,444
47,402
59,500
115,500
75,400
133,800
88,300
100,400
219,200
166,200
166,200219,200100,40088,300133,80075,400115,50059,50047,40249,44446,4243,7786,188759,93215,39116,42719,536662081,6965571,1451,7881,4547009,900
   > Long-term Assets 
1,900
7,200
28,525
143,119
42,709
89,781
96,666
124,656
201,176
234,557
573,872
727,037
666,581
955,624
958,125
1,178,554
910,213
909,110
900,800
1,431,500
1,633,000
2,048,900
2,447,800
2,845,500
2,664,200
3,616,000
3,616,0002,664,2002,845,5002,447,8002,048,9001,633,0001,431,500900,800909,110910,2131,178,554958,125955,624666,581727,037573,872234,557201,176124,65696,66689,78142,709143,11928,5257,2001,900
       Property Plant Equipment 
1,300
3,800
5,939
6,403
9,120
15,225
17,799
21,802
34,681
69,354
221,066
303,859
306,044
366,046
453,685
464,950
478,421
495,774
489,300
545,700
699,700
738,500
731,600
780,900
861,500
1,045,400
1,045,400861,500780,900731,600738,500699,700545,700489,300495,774478,421464,950453,685366,046306,044303,859221,06669,35434,68121,80217,79915,2259,1206,4035,9393,8001,300
       Goodwill 
0
2,700
17,549
15,365
7,465
13,910
7,465
7,465
7,465
7,465
7,465
8,763
2,487
8,123
10,530
10,703
10,264
10,264
10,300
13,700
31,500
28,000
28,000
28,000
28,000
33,700
33,70028,00028,00028,00028,00031,50013,70010,30010,26410,26410,70310,5308,1232,4878,7637,4657,4657,4657,4657,46513,9107,46515,36517,5492,7000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
132,849
343,899
0
448,134
122,658
38,002
2,300
502,700
442,600
767,500
1,149,600
1,649,900
1,316,200
1,909,800
1,909,8001,316,2001,649,9001,149,600767,500442,600502,7002,30038,002122,658448,1340343,899132,849000000000000
       Intangible Assets 
0
2,700
17,549
15,365
14,466
13,910
13,432
12,952
3,140
962
373
9,655
7,374
13,964
5,878
3,412
19,201
18,114
23,500
31,900
139,300
130,300
130,100
16,600
16,500
80,500
80,50016,50016,600130,100130,300139,30031,90023,50018,11419,2013,4125,87813,9647,3749,6553739623,14012,95213,43213,91014,46615,36517,5492,7000
       Long-term Assets Other 
600
700
5,037
121,350
19,123
60,646
65,435
29,939
52,589
53,336
22,974
15,187
10,570
27,724
26,782
53,268
97,819
154,280
197,100
224,100
224,200
154,600
169,900
108,200
114,300
151,800
151,800114,300108,200169,900154,600224,200224,100197,100154,28097,81953,26826,78227,72410,57015,18722,97453,33652,58929,93965,43560,64619,123121,3505,037700600
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
202,135
190,745
0
192,718
0
192,676
178,300
113,400
95,700
0
0
0
0
0
0000095,700113,400178,300192,6760192,7180190,745202,135000000000000
> Total Liabilities 
2,000
6,300
15,907
15,722
12,908
11,737
15,522
16,311
273,944
291,228
363,620
398,535
547,749
569,591
531,732
783,256
618,836
584,798
463,400
777,600
612,400
1,133,000
1,219,800
1,210,200
1,247,800
1,182,200
1,182,2001,247,8001,210,2001,219,8001,133,000612,400777,600463,400584,798618,836783,256531,732569,591547,749398,535363,620291,228273,94416,31115,52211,73712,90815,72215,9076,3002,000
   > Total Current Liabilities 
1,800
4,600
11,492
10,798
9,307
10,618
13,864
14,523
19,250
272,760
57,826
330,187
428,686
212,577
176,755
687,674
504,310
440,824
332,500
444,700
276,600
463,000
323,300
305,400
343,200
804,400
804,400343,200305,400323,300463,000276,600444,700332,500440,824504,310687,674176,755212,577428,686330,18757,826272,76019,25014,52313,86410,6189,30710,79811,4924,6001,800
       Short-term Debt 
0
100
71
102
111
773
16
15
10
250,012
0
220,272
235,968
0
0
282,458
126,481
5,387
0
250,000
0
250,000
0
0
0
400,000
400,000000250,0000250,00005,387126,481282,45800235,968220,2720250,012101516773111102711000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
126,414
5,400
0
250,000
0
250,000
0
0
0
400,000
400,000000250,0000250,00005,400126,4140000000000000000
       Accounts payable 
1,700
2,300
5,952
6,667
2,988
4,326
6,127
3,980
3,093
2,000
20,334
18,750
16,146
47,257
10,203
6,708
6,995
7,502
8,100
8,400
23,100
9,900
4,100
3,800
4,100
5,600
5,6004,1003,8004,1009,90023,1008,4008,1007,5026,9956,70810,20347,25716,14618,75020,3342,0003,0933,9806,1274,3262,9886,6675,9522,3001,700
       Other Current Liabilities 
100
2,200
5,469
575
1,757
60
32
134
882
2,806
37,492
61,401
126,292
165,320
166,552
25,016
10,346
57,462
324,400
436,300
253,500
39,600
319,200
301,600
339,100
71,000
71,000339,100301,600319,20039,600253,500436,300324,40057,46210,34625,016166,552165,320126,29261,40137,4922,80688213432601,7575755,4692,200100
   > Long-term Liabilities 
200
1,700
4,415
4,924
3,601
1,119
1,658
1,788
254,694
18,468
305,794
68,348
119,063
357,014
354,977
95,582
114,526
143,974
130,900
313,700
316,600
670,000
896,500
904,800
904,600
377,800
377,800904,600904,800896,500670,000316,600313,700130,900143,974114,52695,582354,977357,014119,06368,348305,79418,468254,6941,7881,6581,1193,6014,9244,4151,700200
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
68,929
265,632
0
3,724
0
0
0
250,000
250,000
600,000
800,000
800,000
800,000
0
0800,000800,000800,000600,000250,000250,0000003,7240265,63268,929000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
202,135
190,745
0
192,718
0
192,676
178,300
113,400
95,700
0
0
0
0
0
0000095,700113,400178,300192,6760192,7180190,745202,135000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
10,882
10,882
0
45,037
0
11,095
10,900
19,200
19,200
0
0
0
0
0
0000019,20019,20010,90011,095045,037010,88210,882000000000000
       Other Liabilities 
0
0
2,579
3,088
1,834
1,094
1,648
1,780
3,100
7,584
15,673
27,139
39,252
80,500
79,967
91,858
114,526
155,100
141,800
82,900
85,800
67,000
79,400
104,800
76,800
0
076,800104,80079,40067,00085,80082,900141,800155,100114,52691,85879,96780,50039,25227,13915,6737,5843,1001,7801,6481,0941,8343,0882,57900
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,800
9,300
9,300
6,900
10,500
0
010,5006,9009,3009,3008,80000000000000000000000
> Total Stockholder Equity
16,700
53,600
234,738
196,399
171,658
167,765
191,636
275,102
204,606
295,790
507,699
653,009
883,886
948,488
1,094,863
1,304,311
1,265,574
1,599,647
1,862,200
2,101,800
2,788,600
2,780,400
3,395,200
3,958,900
4,796,700
5,984,800
5,984,8004,796,7003,958,9003,395,2002,780,4002,788,6002,101,8001,862,2001,599,6471,265,5741,304,3111,094,863948,488883,886653,009507,699295,790204,606275,102191,636167,765171,658196,399234,73853,60016,700
   Common Stock
0
200
207
208
215
218
229
239
246
266
276
567
600
615
621
630
660
690
700
700
700
700
700
700
700
700
7007007007007007007007006906606306216156005672762662462392292182152082072000
   Retained Earnings 
-15,800
-49,300
-124,882
-162,170
-185,821
-195,390
-180,341
-115,325
-41,360
-21,501
-78,514
-74,746
31,170
249,038
553,480
728,040
1,068,114
1,719,753
2,433,500
2,845,600
3,434,800
3,325,200
3,839,200
4,315,000
5,042,300
6,027,100
6,027,1005,042,3004,315,0003,839,2003,325,2003,434,8002,845,6002,433,5001,719,7531,068,114728,040553,480249,03831,170-74,746-78,514-21,501-41,360-115,325-180,341-195,390-185,821-162,170-124,882-49,300-15,800
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
928,690
992,718
0
1,057,224
0
1,790,620
1,813,500
1,854,300
1,940,200
2,047,900
2,148,700
2,245,400
2,388,400
0
02,388,4002,245,4002,148,7002,047,9001,940,2001,854,3001,813,5001,790,62001,057,2240992,718928,690000000000000
   Treasury Stock0000-2,579,200-2,579,200-2,579,200-2,379,600-1,902,110-1,185,825-513,437-470,998-282,998-67,399-67,395-67,395-231,619-164,560-6,874-6,874-6,874-6,874-6,874-4,07200
   Other Stockholders Equity 
32,500
102,900
359,904
359,728
357,256
361,263
369,071
386,595
244,244
316,708
591,850
731,502
861,291
709,720
544,837
543,787
190,316
-111,490
-566,100
-744,100
-658,200
-531,300
-430,500
-333,800
-190,800
-30,200
-30,200-190,800-333,800-430,500-531,300-658,200-744,100-566,100-111,490190,316543,787544,837709,720861,291731,502591,850316,708244,244386,595369,071361,263357,256359,728359,904102,90032,500



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,327,500
Cost of Revenue-257,500
Gross Profit2,070,0002,070,000
 
Operating Income (+$)
Gross Profit2,070,000
Operating Expense-885,100
Operating Income1,184,9001,184,900
 
Operating Expense (+$)
Research Development408,000
Selling General Administrative395,300
Selling And Marketing Expenses81,800
Operating Expense885,100885,100
 
Net Interest Income (+$)
Interest Income162,700
Interest Expense-59,300
Other Finance Cost-0
Net Interest Income103,400
 
Pretax Income (+$)
Operating Income1,184,900
Net Interest Income103,400
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,274,3001,198,900
EBIT - interestExpense = 1,274,300
1,274,300
1,044,100
Interest Expense59,300
Earnings Before Interest and Taxes (EBIT)1,333,6001,333,600
Earnings Before Interest and Taxes (EBITDA)1,386,800
 
After tax Income (+$)
Income Before Tax1,274,300
Tax Provision-289,500
Net Income From Continuing Ops984,800984,800
Net Income984,800
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,142,600
Total Other Income/Expenses Net-14,000-103,400
 

Technical Analysis of United Therapeutics Corporation
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of United Therapeutics Corporation. The general trend of United Therapeutics Corporation is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine United Therapeutics Corporation's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of United Therapeutics Corporation.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 255.52 < 257.88 < 258.31.

The bearish price targets are: 250.89 > 250.36 > 241.37.

Tweet this
United Therapeutics Corporation Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of United Therapeutics Corporation. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

United Therapeutics Corporation Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of United Therapeutics Corporation. The current macd is 1.94896187.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the United Therapeutics Corporation price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for United Therapeutics Corporation. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the United Therapeutics Corporation price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
United Therapeutics Corporation Daily Moving Average Convergence/Divergence (MACD) ChartUnited Therapeutics Corporation Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of United Therapeutics Corporation. The current adx is 16.21.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy United Therapeutics Corporation shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
United Therapeutics Corporation Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of United Therapeutics Corporation. The current sar is 226.34.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
United Therapeutics Corporation Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of United Therapeutics Corporation. The current rsi is 68.03. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
United Therapeutics Corporation Daily Relative Strength Index (RSI) ChartUnited Therapeutics Corporation Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of United Therapeutics Corporation. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the United Therapeutics Corporation price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
United Therapeutics Corporation Daily Stochastic Oscillator ChartUnited Therapeutics Corporation Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of United Therapeutics Corporation. The current cci is 466.26.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
United Therapeutics Corporation Daily Commodity Channel Index (CCI) ChartUnited Therapeutics Corporation Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of United Therapeutics Corporation. The current cmo is 46.87.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
United Therapeutics Corporation Daily Chande Momentum Oscillator (CMO) ChartUnited Therapeutics Corporation Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of United Therapeutics Corporation. The current willr is -11.89035244.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
United Therapeutics Corporation Daily Williams %R ChartUnited Therapeutics Corporation Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of United Therapeutics Corporation.

United Therapeutics Corporation Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of United Therapeutics Corporation. The current atr is 7.18692339.

United Therapeutics Corporation Daily Average True Range (ATR) ChartUnited Therapeutics Corporation Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of United Therapeutics Corporation. The current obv is 5,271,710.

United Therapeutics Corporation Daily On-Balance Volume (OBV) ChartUnited Therapeutics Corporation Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of United Therapeutics Corporation. The current mfi is 55.81.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
United Therapeutics Corporation Daily Money Flow Index (MFI) ChartUnited Therapeutics Corporation Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for United Therapeutics Corporation.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

United Therapeutics Corporation Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of United Therapeutics Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5068.028
Ma 20Greater thanMa 50236.460
Ma 50Greater thanMa 100235.127
Ma 100Greater thanMa 200229.398
OpenGreater thanClose243.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of United Therapeutics Corporation with someone you think should read this too:
  • Are you bullish or bearish on United Therapeutics Corporation? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about United Therapeutics Corporation? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about United Therapeutics Corporation

I send you an email if I find something interesting about United Therapeutics Corporation.


Comments

How you think about this?

Leave a comment

Stay informed about United Therapeutics Corporation.

Receive notifications about United Therapeutics Corporation in your mailbox!